AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00703625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Study NCT00703625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT03629119 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Supplement
Description: Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
Study NCT04090762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conditional cash transfer
Description: Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
Study NCT03018626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomycin (10 mg) given IV on days 1 and 5
Study NCT04341675 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.
Study NCT04341675 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT01380158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cup pessary (Bioteque America, Inc)
Description: Placement of cup pessary in the vagina after randomization
Study NCT00003117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00003117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01249872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE
Description: Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Study NCT01249872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE
Description: Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Study NCT01249872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE
Description: Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Study NCT01249872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Description: Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Study NCT01249872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE
Description: Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Study NCT01249872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Description: Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus b Conjugate Vaccine
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus b Conjugate Vaccine
Description: Pharmaceutical form:Solution for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus Vaccine, Live, Oral, Pentavalent
Description: Pharmaceutical form:Oral solution Route of administration: Oral, 2 mL
Study NCT04090762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk information provision
Description: Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
Study NCT00878722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXD101
Study NCT00878722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study NCT04620018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
Study NCT02375048 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated WBI
Description: Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
Study NCT02375048 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
Study NCT00293176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo tablets.
Study NCT01552369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
Study NCT01552369 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valganciclovir, 900 mg given orally once daily to all Prophylaxis group subjects for 100 days post transplantation as prophylaxis. Valganciclovir, 900 mg given orally twice daily to Preemptive Therapy group subjects as a PET only after a positive CMV PCR test and stopped after PCR is negative for 2 consecutive weeks.
Study NCT00545779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: 150 mg orally once monthly for 6 months
Study NCT03643237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game-based intervention
Description: The intervention will be administered via an online graphic-adventure video game. It includes 3 components: depression prevention, cognitive stimulation, and healthy habits promotion. The depression prevention component will be adapted from an indicated depression prevention program based on the model by Lewinsohn, Hoberman, Teri, \& Hautzinger, which is effective in short and long terms. The cognitive stimulation component is based on cognitive reserve and cerebral neuroplasticity. The healthy habits promotion component is based on the social learning and social cognitive theories. The App will allow participants to expand information, check progression, and receive reminders about homework
Study NCT03643237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The active control group will have access to a platform of online therapeutically inactive information related to active aging.
Study NCT03762746 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A custom TMS stimulator (MagStim) is used to generate repetitive biphasic magnetic pulses. Magnetic pulses are delivered with a figure-8-coil (Magnetic Coil Transducer). During the experiment, rTMS pulse intensity is adjusted to 90% of the motor threshold. Patients will be randomly assigned to receive a 1 Hz. The target area is stimulated for 10 consecutive days. Stimulation at 1 Hz was applied once a day for 10-days
Study NCT03762746 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control group is receiving treatment as usual. EEG recording and psychopathological ratings are performed one day before the start and on the last day of the study
Study NCT03381937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech trial
Description: speech trial during different ventilation conditions
Study NCT00626041 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: participant referral to primary care network physician
Description: blood pressure, cholesterol and hemoglobin A1c screening and management
Study NCT03144401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: mesotac
Study NCT03144401 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical to the misoprostol tablet but without the active ingredient
Study NCT00094276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Asthma Communication Intervention (FACI)
Description: A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
Study NCT00094276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Asthma Communication Intervention (FACI)
Description: A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B Vaccine
Description: Pharmaceutical form:Suspension for injection Route of administration: Intramuscular, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps, and Rubella Virus Vaccine Live
Description: Pharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
Study NCT03691610 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Virus Vaccine Live
Description: Pharmaceutical form:Suspension for injection Route of administration: Subcutaneous, 0.5 mL
Study NCT04413435 — intervention group
Intervention type: OTHER
Intervention: File Scanning
Description: The patients' epidemiological, clinical, laboratory, and radiological characteristics and treatment and outcomes data will accessed from Hospital Data Management System (HDMS) of Konya Training and Research Hospital and Public Health Management System (PHMS) of Ministry of Health.
Study NCT00635947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic solution
Description: 1.5 L- during 2-4hours
Study NCT00635947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water
Description: 1.5 L- during 2-4hours
Study NCT03118219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive adjustment coping intervention
Description: see arm description
Study NCT00635947 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: 200mL- during 2-4hours
Study NCT03118219 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brainteaser
Description: see arm description
Study NCT05545618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA and 18F-FDG-PET/CT
Description: 18F-FDG-PET/CT imaging and comprehensive assessment of coronary plaque with CCTA within 90 days
Study NCT03040752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine 20 Mg
Description: nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
Study NCT03040752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritodrine Oral Tablet
Description: Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
Study NCT04814459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOP-UP-PT Program
Description: Interventions provided to EG participants included; (1) the Otago Exercise Program (OEP) which is a well-established exercise program with evidence that it reduces falls among community-dwelling older adults, (2) motivational interviewing (MI) to optimize positive health behaviors, and (3) home and environmental modification recommendations aimed at safety. Participants were provided with and educated on the use of a wrist-worn activity tracker and an automated BP monitor unit. Finally, when follow up items were identified (e.g., orthostatic hypotension, community exercise classes), these referrals were made and documented.
Study NCT02014441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10\^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10\^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
Study NCT03566407 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Colonoscopy will be required for all subjects at 6 months - Visit 3.
Study NCT02281682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
Study NCT02227329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Prophylactic ELT will be administered at the time when the HPN is not being infused.
Study NCT02227329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Lock
Description: 3 mL of 100 U/ml heparin
Study NCT02227329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Study NCT02227329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study NCT02281682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
Study NCT00094276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathmobile intervention
Description: A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
Study NCT02731703 — intervention group
Intervention type: DEVICE
Intervention: Overdenture treatment
Description: Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
Study NCT02281682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate
Description: during 3 (consecutive) days once daily. Prior to treatment: curettage
Study NCT02281682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: methylaminolevulinate photodynamic therapy
Description: methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
Study NCT03187496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Each subject will receive midazolam on Days 1 and 12.
Study NCT03187496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Each subject will receive caffeine on Days 1 and 12.
Study NCT00094276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathmobile intervention
Description: A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
Study NCT03447873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue with triple therapy
Description: To continue with triple therapy
Study NCT03447873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to DTG + 3TC
Description: Switch to dolutegravir + lamivudine once daily
Study NCT00972504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK835726 10mg
Description: GSK835726 10mg tablet
Study NCT00972504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1004723 1000mcg
Description: GSK1004723 1000mcg nasal spray solution
Study NCT01880255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
Study NCT00972504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine 10mg
Description: Cetirizine 10mg active comparator
Study NCT00972504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match actives
Study NCT00732368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.